Within the groups of HER2 positive and triple- negative breast cancer, that by classical prognostic signatures are collectively defined as more aggressive breast cancer types, it serves as independent prognostic and predictive factor and can identify tumors with a presumable better prognosis and/or improved treatment response [52]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.